Search

Displaying results 5221 - 5230 of 10000 in total
  1. Drug

    Prolectin-M

    go.drugbank.com/drugs/DB16521
    Investigational

    [L31343] It is being investigated in the clinical trial NCT04512027 (Prolectin-M in COVID-19 Patients Having Mild to Moderate Symptoms Not Requiring Oxygen Support. (Prolectin-M)). … Prolectin-M is a (1-6)-alpha-D-mannopyranose[L31338] and acts as an antagonist of galectin.

  2. Drug

    Clomocycline

    go.drugbank.com/drugs/DB00453
    Experimental

    Clomocycline is a tetracycline used to treat bacterial infections.

  3. Drug

    Brivudine

    go.drugbank.com/drugs/DB03312
    ApprovedInvestigational

    Brivudine is used in the treatment of herpes zoster. Although not approved in the U.S. or Canada, it is approved in several European countries.

  4. Drug

    Polaprezinc

    go.drugbank.com/drugs/DB09221
    Investigational

    It was determined that polaprezinc may be effective in pressure ulcer treatment [A31856]. … Polaprezinc is a chelated form of zinc and L-carnosine. It is a zinc-related medicine approved for the first time in Japan, which has been clinically used to treat gastric ulcers [L1307, L1308].

  5. Drug

    Ulimorelin

    go.drugbank.com/drugs/DB12128
    Investigational

    Ulimorelin is a novel small molecule ghrelin agonist being developed by Tranzyme Pharma as a first-in-class treatment for both POI and diabetic gastroparesis, serious medical conditions in which motility … of the GI tract is severely impaired.

  6. Drug

    ACE393

    go.drugbank.com/drugs/DB05071
    Investigational

    ACE393 is an injectable vaccine designed to combat the bacterium Campylobacter jejuni, one of the greatest causes of bacterial diarrhoeal infections in the developed world.

  7. Drug

    Anagliptin

    go.drugbank.com/drugs/DB12417
    Investigational

    Anagliptin is under investigation for the treatment of LDL Cholesterol, Coronary Disease, Diabetes Mellitus, Glycosylated Hemoglobin, and Dipeptidyl-Peptidase 4 Inhibitors.

    Categories: DPP-IV Inhibitors
  8. Drug

    NTx-265

    go.drugbank.com/drugs/DB05649
    Investigational

    In May 2006, biotechnology company Stem Cell Therapeutics started a Phase IIa study of NTx-265. … NTx-265 is a combination of two currently marketed large molecules designed to stimulate the growth and differentiation of neural stem cells in adults who have suffered a stroke – the second leading cause

  9. Drug

    Opaganib

    go.drugbank.com/drugs/DB12764
    Investigational

    [L27436] This drug has potential anticancer, anti-inflammatory, and antiviral activities, with potential applications in oncology, inflammation, the gastrointestinal system, and COVID-19. … Opaganib, also known as ABC294640, is a selective [sphingosine kinase-2 (SK2)](https://go.drugbank.com/polypeptides/Q9NRA0) inhibitor that is orally administered.

  10. Drug

    Lumefantrine co-artemether

    go.drugbank.com/drugs/DB13085
    ApprovedInvestigationalWithdrawn

    Unlike artemether, lumefantrine has a slower onset of action, resulting in clearance of residual parasites and a decrease in recrudescence rate. … The combination is an effective and well-tolerated malaria treatment, providing high cure rates even in areas of multi-drug resistance.